Given the 4% prevalence of the TP53 mutations among Polish patients, we suggest that all patients who develop BRCA-negative breast cancer ≤ 30 years and have a positive family history of LFS-related cancers should be screened for TP53 variants. The gene discussed is TP53; the disease is cancer.